The shortage of certain cancer drugs is a serious and life-threatening issue for cancer patients across the United States. This, however, is not a new issue. Drug shortages are a cyclical event, and we need a durable solution to ensure that cancer patients have access to the drugs and the treatment they need to survive.
When Larry Einhorn was a young physician in the early 1970s, actinomycin-D was the standard drug used to treat testicular cancer. It was—and still is—the most common carcinoma in young men ages 15-35.
